INNOVA CAPTAB LIMITED
Latest filings
- Innova Captab files quarterly demat compliance certificate · Compliance
- Non-promoter group trims stake by 18 lakh shares at Innova Captab · Ownership Changes
- AGM 2026 voting results: All 10 resolutions passed, board and KMPs re-appointed · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates a pharmaceutical business with two reported segments: CDMO (Contract Development and Manufacturing Organization) at INR 1,133 cr in FY26 (+24% YoY), and Branded Generics at INR 497 cr (+51% YoY). CDMO serves 350+ domestic clients including leading Indian pharma companies, manufacturing drug products to partner specifications. Branded Generics sells branded drug formulations, with a 70% domestic / 30-35% export mix. The Jammu facility completed its first full year with ~INR 300 cr revenue and reached EBITDA breakeven in Q4, exiting at an INR 90 cr+ per quarter run rate. A new Baddi block for general oral solid/liquid capacity requires INR 150-170 cr capex over FY27-FY28, with potential INR 450-500 cr revenue at optimum levels. Materials at 61.7% of revenue are the dominant input cost. Exports contributed 31% of total revenue; UK-MHRA approval for the Baddi cephalosporin facility and PIC/S certification for Jammu blocks open access to regulated international markets.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from INNOVA CAPTAB LIMITED's filed financials and exchange disclosures
What does INNOVA CAPTAB LIMITED do?
INNOVA CAPTAB LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol INNOVACAP.
Is INNOVA CAPTAB LIMITED profitable?
Yes. Over the trailing twelve months INNOVA CAPTAB LIMITED reported a net profit of ₹154 Cr on revenue of ₹1,749 Cr.
Does INNOVA CAPTAB LIMITED pay a dividend?
Yes. The dividend yield is 0.19% at the current price. It paid out 8% of its profit as dividend in FY26.
Is INNOVA CAPTAB LIMITED debt-free?
No. It reported borrowings of ₹344 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹340 Cr after cash. Debt stands at 0.32× equity. That is higher than 69% of its 166 Pharmaceuticals peers.
Is INNOVA CAPTAB LIMITED expensive compared with its peers?
On trailing P/E, INNOVA CAPTAB LIMITED ranks 105 of 158 in Pharmaceuticals — cheaper than 34% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the INNOVA CAPTAB LIMITED share price move in a day?
On a typical session INNOVA CAPTAB LIMITED moves 1.12% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track INNOVA CAPTAB LIMITED's announcements?
Every NSE and BSE filing by INNOVA CAPTAB LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.